Literature DB >> 9694527

Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone.

G Griebel1, G Perrault, D J Sanger.   

Abstract

The present series of experiments compared the behavioral effects of the novel non-peptide CRF antagonist CP-154,526 with those of diazepam and the 5-HT1A receptor partial agonist buspirone in classical animal models of anxiety including conflict tests (punished lever pressing and punished drinking tests in rats) and exploratory models (elevated plus-maze test in rats, light/dark choice and free-exploration tests in mice), and a recently developed mouse defense test battery (MDTB) which has been validated for the screening of anxiolytic drugs. Results from both conflict procedures showed that diazepam (2.5-10 mg/kg, i.p.) produced clear anxiolytic-like effects, whereas buspirone (2.5 mg/kg, i.p.) displayed anticonflict activity in the punished drinking test only. CP-154,526 (0.6-20 mg/kg) was devoid of significant activity in both procedures. In the elevated plus-maze, diazepam (2 mg/kg, i.p.) produced significant effects on traditional (i.e. spatio-temporal) and ethologically derived (i.e. risk assessment and directed exploration) indices of anxiety. Buspirone (1-4 mg/kg, i.p.) reduced risk assessment activities only, and CP-154,526 (0.6-20 mg/kg, i.p.) did not modify the indices of anxiety in the elevated plus-maze. In the light/dark test, diazepam (2.5-5 mg/kg, i.p.) and CP-154,526 (10-40 mg/kg, i.p.) affected all behavioral indices of anxiety, while buspirone reduced risk assessment activities at the highest doses only (10 and 15 mg/kg, i.p.). In the free-exploration test, diazepam (1 mg/kg, i.p.) reduced avoidance responses towards novelty, as indicated by the increase in exploratory activity in a novel compartment and the decrease in risk assessment. CP-154,526 failed to affect the former behavior and weakly reduced the latter (5 and 20 mg/kg, i.p.). Buspirone (1.25-5 mg/kg, i.p.) was inactive in this test. Finally, in the MDTB, diazepam (0.5-3 mg/kg, i.p.) attenuated all defensive reactions of mice confronted with a rat stimulus (i.e. flight, risk assessment and defensive attack) or with a situation associated with this threat (i.e. contextual defense). Buspirone (1.25-5 mg/kg, i.p.) reduced defensive attack and contextual defense, while CP-154,526 (5-20 mg/kg, i.p.) affected all defensive behaviors, with the exception of one risk assessment measure. The finding that CP-154,526 displayed positive effects in mice but not in rats may be due to increased sensitivity to environmental stress of the strains used (i.e. BALB/c, Swiss) and/or to the fact that animals were exposed to unavoidable stress stimuli which may lead to a significant activation of the CRF system. Although in mice the anxiety-reducing potential of CP-154,526 is superior to that of the atypical anxiolytic buspirone, it is smaller in terms of the magnitude of the effects and the number of indices of anxiety affected than that of diazepam.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694527     DOI: 10.1007/s002130050645

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  The use of sudden darkness in mice: a behavioural and pharmacological approach.

Authors:  Bettina Bert; Luciano F Felicio; Heidrun Fink; Antonia G Nasello
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

3.  Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis.

Authors:  Kendall M Carlin; Wylie W Vale; Tracy L Bale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

4.  Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior.

Authors:  Tracy L Bale; Roberto Picetti; Angelo Contarino; George F Koob; Wylie W Vale; Kuo-Fen Lee
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

5.  Genetic approach for intracerebroventricular delivery.

Authors:  Limor Regev; Eli Ezrielev; Eran Gershon; Shosh Gil; Alon Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

6.  Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems.

Authors:  K H Skelton; C B Nemeroff; D L Knight; M J Owens
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

Review 7.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

8.  A novel social proximity test suggests patterns of social avoidance and gaze aversion-like behavior in BTBR T+ tf/J mice.

Authors:  Erwin B Defensor; Brandon L Pearson; Roger L H Pobbe; Valerie J Bolivar; D Caroline Blanchard; Robert J Blanchard
Journal:  Behav Brain Res       Date:  2010-11-03       Impact factor: 3.332

9.  Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice.

Authors:  Victoria B Risbrough; Richard L Hauger; Mary Ann Pelleymounter; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  The CRF-1 receptor antagonist, CP-154,526, attenuates stress-induced increases in ethanol consumption by BALB/cJ mice.

Authors:  Emily G Lowery; Angela M Sparrow; George R Breese; Darin J Knapp; Todd E Thiele
Journal:  Alcohol Clin Exp Res       Date:  2007-12-21       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.